electroCore, Inc.
Change company Symbol lookup
Select an option...
ECOR electroCore, Inc.
PEP PepsiCo Inc
DPZ Domino's Pizza Inc
KEY KeyCorp
AMH-F American Homes 4 Rent
LYB LyondellBasell Industries NV
CHD Church & Dwight Co Inc
ATHX Athersys Inc
PARR Par Pacific Holdings Inc
EVER EverQuote Inc
Go

Company profile

ElectroCore, Inc., formerly ElectroCore LLC, is a commercial-stage bioelectronic medicine healthcare company. The Company is engaged in developing non-invasive vagus nerve stimulation (nVNS) therapy for the treatment of multiple conditions in neurology, psychiatry, gastroenterology and respiratory fields. The Company's gammaCore is a simple-to-use hand-held device that provides non-invasive dispensing therapy, which stimulates the cervical branch of the vagus nerve. The gammaCore is a non-drug treatment for adults who suffer from episodic cluster and migraine pain. The Company's target is the treatment of primary headaches (migraine and cluster headache), and the associated chronic co-morbidities of gastric motility, psychiatric, sleep and pain disorders.

Postmarket

Last Trade
Delayed
$1.79
-0.085 (-4.53%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$1.88
Day's Change
0.145 (8.38%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
1.89
Day's Low
1.71
Volume
(Heavy Day)
Volume:
857,508

10-day average volume:
679,290
857,508

electroCore to Announce Second Quarter Ended June 30, 2020 Financial Results on Thursday, August 13

4:31 pm ET August 6, 2020 (Globe Newswire) Print

electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report financial results for the second quarter ended June 30, 2020 after the close of the market on Thursday, August 13, 2020. Management will host a conference call and webcast at 4:30pm Eastern Time to discuss the financial results and answer questions.

Thursday, August 13 @ 4:30pm Eastern Time
Domestic:            877-407-4018
International:       201-689-8471
Conference ID:       13706874
Webcast:             http://public.viavid.com/index.php?id=140717

About electroCore, Inc.

electroCore, Inc. is a commercial-stage bioelectronic medicine company dedicated to improving patient outcomes through its platform non-invasive vagus nerve stimulation therapy initially focused on the treatment of multiple conditions in neurology. The company's current indications are the preventative treatment of cluster headache and migraine and acute treatment of migraine and episodic cluster headache.

For more information, visit www.electrocore.com.

Investors:

Hans Vitzthum

LifeSci Advisors

617-430-7578

hans@lifesciadvisors.com

or

Media Contact:

Jackie Dorsky

electroCore

973-290-0097

jackie.dorsky@electrocore.com

https://ml.globenewswire.com/media/b640fa3f-4363-43d9-a795-4a4279b4fd6c/small/ec-logo-2018-tm-rgb-png.png

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.